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Abstract Biosimilars are required to be similar or highly
similar in structure to their biologic reference product but
are neither expected nor required to contain identical active
substances. For example, glycosylated biosimilars
approved to date demonstrate quantitative and qualitative
structural differences from their reference product and
exemplify the latitude of variations permitted for biosimi-
lars. Although differences between a candidate biosimilar
and its reference product will be evaluated for differential
clinical effects during biosimilarity assessment, it is unli-
kely that potential differences between any two indirectly
related biosimilars will be formally evaluated. Further-
more, biosimilar pathways permit variations in pharma-
ceutical attributes, clinical development approaches, and
regulatory outcomes, resulting in further diversity of
attributes among approved biosimilars. Because biosimi-
lars may vary across the ranges of structural and functional
acceptance criteria, they should not be treated like multi-
source, generic drugs.
Key Points
Although biosimilars are highly similar to their
reference products, they are not identical to them.
Regulatory pathways permit slight differences in
structural and other product quality attributes of
biosimilars; such difference are unlikely to be
formally evaluated among indirectly related
biosimilars, resulting in a potential for a broader
range of potential differences in quality attributes
among approved biosimilars.
Policies and practices related to the identification and
use of biosimilars should take into account potential
molecular differences among multiple biosimilars of
the same reference product and should not treat them
like generics.
Specific recommendations to distinguish biologics
from generic drugs in practice include ensuring that all
biologics have distinguishable names and are
prescribed by a distinguishable name, that a clinician
is involved in decisions to switch among non-
interchangeable biologics, and that patient medical
records track biologics by their distinguishable names.
1 Introduction
Biologicmedicines consist ofmixtures of structural isoforms
(e.g., glycoforms), whereas the active ingredient of a
chemically synthesized drug is typically a single entitywith a
defined structure [1]. Unlike generic products for chemically
synthesized drugs, which contain the same active ingredient
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as their reference product, biosimilar products do not contain
active drug substances identical to their reference product
[2–4]. Minor structural differences between biosimilars and
their reference product are expected and allowed because of
their inherent molecular complexity and differences in
manufacturing processes among biologics manufacturers
[4]. However, suchminor structural differences are expected
not to result in functional or clinically meaningful differ-
ences in terms of quality, safety, or efficacy [3].
Beyond the implications for potential differences in drug
substances, biosimilar development pathways also include
opportunities and incentives for diversity in drug product and
clinical attributes, including formulations, presentations,
devices, indications, and routes of administration [5].
Although these features also apply to chemically synthesized
drugs, the nature of the biosimilars pathway may tend to
promote more diversity in these aspects to compensate for
the intrinsic molecular heterogeneity and intellectual prop-
erty. Because biosimilars differ from chemically synthesized
drugs in many critical aspects, policies and practices appli-
cable to generic drugs from multiple manufacturers gener-
ally are not directly transferable to biosimilars [4, 6, 7].
This brief report highlights examples of structural vari-
ances (i.e., at the level of the drug substance) of biosimilars
approved in the European Union (EU) and Japan to illustrate
that biosimilarity is not transitive. We also provide an
example of how interactions between structural attributes
could be relevant to the design of a biosimilar. The biosimilar
approval process relies on a comparison of one biosimilar
candidate with one reference product, whereas multiple
biosimilars of a given reference product can be expected in
the marketplace. Therefore, we suggest that policies and
practices related to the identification and use of biosimilars
take into account the potential molecular differences
between biosimilars and their reference products and the lack
of transitivity among multiple biosimilars of the same ref-
erence product. Specific recommendations to distinguish
biologics from generic drugs in practice include ensuring
that each biologic has a unique name and that it is prescribed
by that unique name, that a clinician is involved in decisions
to switch among non-interchangeable biologics, that patient
medical records track biologics by their unique names, and
that reimbursement claims systems use a unique code for
each individual biosimilar.
2 Differences Between Biosimilars and Reference
Products Necessitate Product-Specific
Identification
A review of glycosylated biosimilars approved in the EU
and in Japan demonstrates that structural variances exist
between biosimilars and their reference products (Table 1).
For example, with Retacrit (epoetin zeta; SB309), an EU-
approved biosimilar of Eprex/Erypo (epoetin alfa), the
extent of glycoforms without an O-linked glycan chain was
found to be higher in the biosimilar than in the epoetin alfa
reference product [8]. Conversely, levels of variants of
sialic acid (N-glycolylneuraminic acid and O-acetyl neu-
raminic acid) were higher in the reference product [8].
Independent studies, as well as our internal analysis
(Table 2) performed after Retacrit (epoetin zeta) was
approved in the EU, have revealed additional structural
differences, including higher levels of lactosamine repeats
and lower levels of sialylation relative to Eprex (epoetin
alfa) [9]. As an example of diversity in drug product for-
mulation or presentation, differences in potency between
these products have also been reported, with the biosimilar
product demonstrating 8 % lower bioactivity relative to the
reference product, likely due to a difference in protein
concentration [8].
Another EU-approved biosimilar of Eprex/Erypo
(epoetin alfa), Binocrit (epoetin alfa; HX-575), contains
higher levels of phosphorylated high mannose glycans
(mannose-6-phosphate glycans) at one glycosylation site,
Asn-24, and lower levels of sialic acid (N-glycolylneu-
raminic acid and diacetylated neuraminic acid) than the
reference product [10]. Independent studies, as well as our
internal analysis (Table 2), performed since Binocrit was
approved, have revealed additional structural differences,
including higher levels of Lewis-X structures relative to
Eprex (epoetin alfa) [9]. No differences in bioactivity
between Eprex (epoetin alfa) and Binocrit (epoetin alfa)
were noted in their respective development studies [10].
The first biosimilar monoclonal antibody approved in
the EU, a biosimilar of Remicade (infliximab) marketed
under the trade names RemsimaTM (infliximab; CT-P13)
and InflectraTM (infliximab), displays lower levels of afu-
cosylated glycan structures relative to the reference product
[11]. These differences correlate with lower binding
affinity for the fragment crystallizable (Fc) receptors Fcc-
RIIIa and FccRIIIb, which mediate certain immunologic
functions [11]. Further, the biosimilar displays lower
antibody-dependent cell-mediated cytotoxicity in certain
in vitro assays [11]. In addition, Ovaleap (follitropin alfa;
XM17), a biosimilar of Gonal-f (follitropin alfa)
approved in the EU, demonstrates differences in sialic acid
content and an increase in nonhuman sialic acid variants
with N-glycolylneuraminic acid, in comparison with the
reference product [12]. Bemfola (follitropin alfa), another
biosimilar of Gonal-f (follitropin alfa), also manifests
minor differences from the reference biologic in its gly-
cosylation profile [13]. For the biosimilar, the ratio of tetra-
antennary:di-antennary structures was slightly higher, there
were slight differences in the distribution of fucosyl resi-
dues in relation to antennarity, and sialic acid residues of
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the a-subunit contained an O-acetyl group not detected in
the reference biologic [13].
An independently developed epoetin biosimilar product
licensed to Japan Chemical Research Pharmaceuticals Co.,
Ltd. (JCR), ‘‘Epoetin alfa BS injection [JCR]; epoetin
kappa,’’ has been approved in Japan. This biosimilar has
isoforms of higher mass (likely due to increased lac-
tosamine extensions) and additional basic isoforms (due to
lower levels of sialylation) in comparison with its reference
product, Espo (epoetin alfa) [9, 14].
In our laboratories, we have used animal models to
study the effects of lactosamine extensions and N-glycan
sialylation on epoetin potency. Increases in N-glycan
branching and sialylation have previously been correlated
with increased epoetin potency, primarily due to their
effect on the epoetin serum half-life [15, 16]. Our studies
showed that increased lactosamine extensions also increase
epoetin potency and that increased levels of lactosamines
could be compensated for by reduced levels of sialylation
(unpublished data). This multifactorial design and
Table 1 Structural variances of approved biosimilar products in the European Union (EU) and Japan
Approved biosimilar Reference product Regulatory
region
Structural differences relative to reference product
Retacrit (epoetin zeta;
SB309)
Eprex/Erypo (epoetin alfa) EU Higher levels of glycoforms lacking occupied O-glycan site [8]




Eprex/Erypo (epoetin alfa) EU High Man-6-P levels detected in clinical study batches [10]
RemsimaTM (infliximab;
CT-P13)
Remicade (infliximab) EU Lower levels of afucosylated variants [11]
Ovaleap (follitropin alfa;
XM17)
Gonal-f (follitropin alfa) EU Slight shift in sialic acid content and increase in nonhuman
sialic acid variants with N-glycolylneuraminic acid [12]
Bemfola (follitropin alfa) Gonal-f (follitropin alfa) EU Minor differences in glycosylation profile [13]
Ratio of tetra-antennary:di-antennary structures slightly higher
[13]
Slight differences in distribution of fucosyl residues in relation
to antennarity [13]
O-acetyl–containing sialic residues of a-subunit below level of
detection [13]
Epoetin alfa BS injection
[JCR] (epoetin kappa)
Espo (epoetin alfa) Japan Isoforms of higher molecular mass [14]
Additional basic isoforms [14]
JCR Japan Chemical Research Pharmaceuticals Co., Ltd., Man-6-P mannose-6-phosphate glycans
Table 2 Reported and
independently assessed
differences in glycation
attributes between two epoetin
biosimilars and their reference
product, Eprex (epoetin alfa)
Attribute Retacrit (epoetin zeta) Binocrit (epoetin alfa)
EPAR Amgen data EPAR Amgen data
O-glycans
Occupancy Lower Lower – Similar
Sialylation – Lower – Higher
N-glycans
Sialylation – Lower – Similar
Lactosamines – Higher – Similar
Lewis-X structures – Similar – Higher
Phosphorylated high mannose – Similar Higher Higher
Sialic acids
Total/epoetin – Lower – Similar
NGNA variant Lower Lower Lower Lower
Acetylated Lower Lower Lower Lower
EPAR European public assessment report [8, 10], NGNA N-glycolylneuraminic acid
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characterization challenge has been characterized in a
guidance document published by the US Food and Drug
Administration (FDA), using the example of lactosamines
and sialylation [17]. In light of two examples of approved
epoetin alfa biosimilars with elevated lactosamine and
reduced sialylation, it is apparent that biosimilar develop-
ment is more complex than simply matching all critical
quality attributes to within the reference product range.
Rather, it is a holistic design problem, and each biosimilar
may represent a unique solution to that problem.
All biosimilar products mentioned here have been
developed through a comprehensive similarity exercise,
which included analytical, nonclinical, and clinical
comparisons with their reference product, and the results
were reviewed by the regulators according to their
respective regulatory frameworks prior to their approval.
In the view of the approving regulators, it is unlikely
that these structural differences will result in clinically
meaningful effects on efficacy and safety in the
approved indications; however, these differences in
product attributes exemplify the latitude in structural
variance permitted in biosimilars. Future development of
additional biosimilars to the same reference product may
bring additional structural diversity as some sponsors
introduce alternative host cell expression systems in their
manufacturing processes. In addition, once biosimilars
are approved, manufacturing changes to either the
biosimilar or the reference product could result in evo-
lution of quality attributes outside the ranges that were
assessed during biosimilar development [18]. However,
there is no requirement to prove biosimilarity again as a
result of product life-cycle management.
The existence of such structural differences between
biosimilars and their reference biologics, as well as
between separately developed biosimilar products of the
same reference product, warrants accurate identification of
the specific drug or active substance. This could be
accomplished by assigning distinguishable names to all
biologics, including biosimilars. Such names could be a
combination of distinguishable nonproprietary names and/
or mandatory trade names to clearly identify biologics
manufactured by independently developed processes.
Given that the FDA has no authority to require brand
names for biosimilars and that some prescribers and
prescribing systems may prefer nonproprietary names, it
may be advisable to assign a distinguishable nonpropri-
etary name to each biosimilar. Specific product identifi-
cation is important in prescribing and dispensing drugs
and in maintaining patient medical records, and it allows
accurate attribution of adverse events to the correct pro-
duct and the relevant manufacturer during postmarketing
pharmacovigilance [19–21].
3 Biosimilarity Is Not Transitivity
The relationship between a given biosimilar product and its
reference product is not transitive to other biosimilars. This
is a natural consequence of the fact that biosimilars are not
structurally identical to their reference biologic products or
to each other. Each biosimilar differs from its reference
product in its own unique manner and is permitted to differ
in terms of quantitative and qualitative structural aspects as
a result of differences in manufacturing processes [3].
Indeed, there is no regulatory requirement to ensure that all
biosimilars of a particular reference biologic differ in a
similar qualitative manner or to the same extent. The
manufacturing details and history of the originator refer-
ence product will be unknown to the biosimilar sponsor.
Therefore, biosimilar sponsors must independently char-
acterize the reference product, evaluate biosimilarity in the
context of the equivalence window (i.e., the range of pro-
duct quality attributes that was established by the biosim-
ilar sponsor during the evaluation for its licensure [18]),
and establish postapproval controls. It should be noted that
product quality attributes of the biosimilar are not neces-
sarily required to fall within the same range of variability
as the reference product and that the biosimilar equivalence
window and the proven acceptable range of quality attri-
butes of the reference product, each justified independently
to regulatory agencies, are likely to differ (Fig. 1) [18].
For recombinant human erythropoietins, glycosylation
has been linked to in vivo biologic activity, and certain
features of N-linked glycan heterogeneity are considered
critical quality attributes [22]. Glycoform profiling of three
epoetin reference products and three epoetin biosimilars,
using liquid chromatography/mass spectrometry–electro-
spray ionization, has shown a unique characteristic pattern
of glycoforms for each product [9]. Additionally, a prin-
cipal component analysis, using liquid chromatogra-
phy/mass spectrometry to assess glycan heterogeneities
among nine recombinant epoetin products, found that four
epoetin biosimilars did not plot close to the reference
biologic, indicating relative differences in glycan hetero-
geneities [22]. These data demonstrate that not only do the
epoetin biosimilars differ from the reference product in
glycosylation but also the difference among biosimilars can
be greater than the difference between each biosimilar and
the reference drug. Further, these data demonstrate that
biosimilars have multidimensional structural heterogeneity
and proprietary quality specifications, and they lack tran-
sitive properties of identity.
The practical implication of biosimilar diversity is that
biosimilars should not be used in practice in the same
manner as multiple-source (i.e., multisource) generic
drugs. Multisource drugs are a set of generic equivalents to
368 G. Grampp, S. Ramanan
a given brand drug [23]. In the USA, multisource drugs are
commonly treated as an interchangeable commodity for
which a prescriber need not select any particular version
(i.e., prescribing by generic name is encouraged), and
switching among generic equivalents is commonly prac-
ticed at the pharmacy level without prescriber awareness or
involvement. In the USA, multisource drugs administered
under a medical benefit typically receive the same drug
billing and payment code, reflecting their status as an
interchangeable commodity [24]. Furthermore, adverse
event reports are often assigned to the product class or are
misattributed to the originator brand [7, 25].
None of these generic drug practices are advisable for
biosimilars. Availability of multiple biosimilar versions of
a single biologic reference product is expected as the
biosimilar industry matures; this is already a reality for
some product classes in Europe. To avoid inadvertent
switching and to ensure traceability of adverse events to the
appropriate biologic or biosimilar, EU policymakers have
emphasized that they should be prescribed and tracked by
unique names (typically brand names) [21]. In the USA,
the first biosimilar has been given a distinguishable non-
proprietary name (i.e., filgrastim-sndz) to facilitate phar-
macovigilance and prevent inadvertent switching [26].
Policymakers have also emphasized that clinicians should
be involved in decisions to switch patients from one bio-
logic to another, although an exception may be made in the
USA for a biosimilar determined by the FDA to be inter-
changeable with its reference product [27]. These policies
have been recommended in recognition of the complex
relationship between a given biosimilar and its reference
product, but they are also relevant when one considers the
undefined relationships among a set of similar biologics
(i.e., multiple biosimilars of a single reference product).
Another practical implication of biosimilar diversity is that
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(lower sialylation, higher lactosamine) 
Reduced sialic acid variant levels 
(N-glycolyl and acetylated) 
Modified formulation 
(different excipients: polysorbate 20, 
leucine, isoleucine, threonine, 
glutamic acid, phenylalanine) 
Stability  
(24-month shelf life for dosage strengths 
1,000 IU, 2,000 IU and 3,000 IU)  
Reduced sialic acid variant levels 
(N-glycolyl and acetylated)
Elevated O-site sialylation 
Elevated Man-6-P, Lewis-X 
SC administration not authorized 
in chronic kidney disease 
Fig. 1 Biosimilar 1 = biosimilar 2. Retacrit (epoetin zeta) and
Binocrit (epoetin alfa), biosimilars of Eprex/Erypo (epoetin alfa),
differ substantially from each other in multiple parameters [8, 10, 33].
The elements of a drug substance are shown on the x axis (i.e., the
expression system, glycosylation, critical quality attributes [CQAs],
and new or atypical species). The elements of a drug product are
shown on the y axis (i.e., the formulation, container closure, stability,
and other features). The clinical elements are shown on the z axis (i.e.,
the indications, route of administration, and/or immunogenicity
profile). The green dot represents the reference product. The blue
dots represent the differences between the reference product and
Binocrit. The orange dots represent the differences between the
reference product and Retacrit. Difference in this context means
either new product variants (quality attributes) not found in the
reference product, or product variant/attribute levels outside the range
of the reference product. Man-6-P mannose-6-phosphate glycans,
SC subcutaneous
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medical benefit should have a unique reimbursement code
to facilitate traceability of adverse events to a particular
manufacturer via active surveillance tools such as the
FDA’s Sentinel program [28].
4 Other Sources of Diversity
We have focused primarily on the sources and conse-
quences of structural diversity of biologics at the level of
the drug substance. Beyond these considerations, biosimi-
lar sponsors may also consider options for different for-
mulations, containers, or devices to improve shelf-life,
handling, or convenience to patients or healthcare provi-
ders [5, 29]. For example, biosimilar filgrastim and fol-
litropin alfa products approved in the EU have been
developed with different formulations and/or strengths
relative to their reference products and to each other [30–
36]. Formulations and containers can, in turn, influence
structural attributes and stability profiles of biologics,
potentially creating additional sources of variation in the
physicochemical attributes of the active substances
administered to patients [37].
Furthermore, biosimilar developers may be granted a
subset of the clinical indications or other conditions of use
(e.g., routes of administration) of the reference products
[5]. These considerations are not unique to biologics, but
when they are coupled with the diversity of development
choices for design of drug substances and drug products, it
is likely that a given set of related biosimilar products
could possess a diverse and nontransitive collection of
structural, pharmaceutical, and clinical characteristics. In
such circumstances, it may not be appropriate to view the
entire class as a set of fully interchangeable therapeutic
equivalents but, rather, as therapeutic alternatives. There is
nothing derogatory toward biosimilars in this observation;
it is merely a reflection of the practical reality of the nature
of biosimilar development and the incentives for individual
choices in commercialization and life-cycle management.
Current regulations do not require multiple biosimilars
to be similar to each other, nor do they require a given
biologic to remain similar to any other biologic over time.
Therefore, cumulative changes in the relative levels of
N-glycan sialylation and lactosamine repeats due to plan-
ned changes (i.e., product evolution) or unknown devia-
tions (i.e., drift) in manufacturing processes of any of the
erythropoietins could potentially result in a difference in
the required dose for a given patient among various epoetin
products [18]. Similar opportunities for divergence in
functionally relevant product attributes could emerge for
other classes of glycosylated biologics, including mono-
clonal antibodies subject to future biosimilar competition.
5 Conclusions
Regulatory pathways for biosimilars anticipate and allow
for flexibility in the nature and composition of structural
variants and other attributes of biosimilars. Although this
flexibility is critical for the successful development of new
biosimilars, the range of variability for quality attributes of
a biosimilar may not fall within the same range accepted
for the reference product. As biosimilars of more complex
reference products have been developed (e.g., glycosylated
erythropoietins, follitropins, and monoclonal antibodies),
there has been no decrease in the prevalence of structural
and quality differences [8, 10, 12, 13]. The examples
summarized above demonstrate that similarity may not be
transitive to other biosimilars of the same reference prod-
uct. Because the specifications for posttranslational modi-
fications and other quality attributes of a biosimilar will
likely vary from those of the reference product, owing to
the complexity of biologics and their manufacturing pro-
cesses, biosimilars should not be considered to have the
‘‘same’’ active substance as their reference product or other
biosimilars of the same reference product. Although dif-
ferences in structure between a candidate biosimilar and its
reference product will be evaluated in functional, non-
clinical, and clinical studies to assess biosimilarity and to
demonstrate the lack of clinically meaningful differences,
the potential differential clinical effects between any two
biosimilars of the same reference product will not likely be
formally evaluated. Specific differences or combinations of
differences relative to the reference product may not
exceed the bounds of a clinically meaningful effect on
safety or efficacy, but the cumulative effect of differences
between biosimilars might have a clinically meaningful
effect. Because biosimilars vary from their reference bio-
logic product and from each other in quality attributes and
possibly in other pharmaceutical and clinical attributes,
they should not be treated like generics from multiple
manufacturers. Rather, they should be considered as indi-
vidual therapeutic alternatives. In practice, this means that
biosimilars should each be assigned a unique name, they
should be prescribed and tracked in medical records by a
unique name, and clinicians should be involved in deci-
sions to switch patients among similar biologics, particu-
larly when the FDA has not determined a given biosimilar
to be interchangeable with the prescribed biologic.
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